MetaADEDB 2.0 @ LMMD
ceftolozane, tazobactam drug combination
(GRHWKSLBMDQBQW-KZVOOCJBSA-N)
Structure
SMILES
OC(=O)[C@@H]1N2C(=O)CC2S(=O)(=O)[C@@]1(C)Cn1ccnn1.NCCNC(=O)Nc1c[n+](n(c1N)C)CC1=C(C(=O)[O-])N2[C@H](SC1)[C@@H](C2=O)NC(=O)/C(=N/OC(C(=O)O)(C)C)/c1nsc(n1)N
Molecular Formula:
C33H42N16O13S3
Molecular Weight:
966.981
Log P:
-1.7524
Hydrogen Bond Acceptor:
30
Hydrogen Bond Donor:
8
TPSA:
486.59
CAS Number(s):
1613740-46-7
Synonym(s)
1.
ceftolozane, tazobactam drug combination
2.
Zerbaxa
3.
ceftolozane - tazobactam
4.
ceftolozane sulfate - tazobactam
5.
ceftolozane sulfate, tazobactam drug combination
External Link(s)
MeSHC000594038
PubChem Compound86291594
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1No adverse eventFAERS: 52US FAERS
2Product use in unapproved indicationFAERS: 37US FAERS
3Product use issueFAERS: 37US FAERS
4Pathogen resistanceFAERS: 18US FAERS
5OverdoseFAERS: 15US FAERS
6Adverse eventFAERS: 14US FAERS
7Drug resistanceFAERS: 14US FAERS
8Incorrect dose administeredFAERS: 13US FAERS
9treatment failureFAERS: 13US FAERS
10Drug ineffectiveFAERS: 12US FAERS
11Circumstance or information capable of leading to medication errorFAERS: 8US FAERS
12Product quality issueFAERS: 6US FAERS
13Drug effective for unapproved indicationFAERS: 4US FAERS
14Drug ineffective for unapproved indicationFAERS: 4US FAERS
15HypotensionFAERS: 4US FAERS
16Acute kidney injuryFAERS: 3US FAERS
17Antimicrobial susceptibility test resistantFAERS: 3US FAERS
18Cardiac ArrestFAERS: 3US FAERS
19Expired product administeredFAERS: 3US FAERS
20Incorrect product storageFAERS: 3US FAERS
21SepsisFAERS: 3US FAERS
22Anastomotic complicationFAERS: 2US FAERS
23Atrial FibrillationFAERS: 2US FAERS
24ClonusFAERS: 2US FAERS
25Clostridium difficile infectionFAERS: 2US FAERS
26Depressed Level of ConsciousnessFAERS: 2US FAERS
27Disease ProgressionFAERS: 2US FAERS
28InfectionFAERS: 2US FAERS
29OsteomyelitisFAERS: 2US FAERS
30Pancreatic carcinomaFAERS: 2US FAERS
31Physical product label issueFAERS: 2US FAERS
32PneumoniaFAERS: 2US FAERS
33Product preparation errorFAERS: 2US FAERS
34Product storage errorFAERS: 2US FAERS
35Respiratory FailureFAERS: 2US FAERS
36Septic ShockFAERS: 2US FAERS
37ThrombocytopeniaFAERS: 2US FAERS
38White blood cell count decreasedFAERS: 2US FAERS
39Accidental overdoseFAERS: 1US FAERS
40Acute respiratory failureFAERS: 1US FAERS
41AgranulocytosisFAERS: 1US FAERS
42Angina PectorisFAERS: 1US FAERS
43AngioedemaFAERS: 1US FAERS
44Antibiotic therapyFAERS: 1US FAERS
45Aspergillus test positiveFAERS: 1US FAERS
46BlindnessFAERS: 1US FAERS
47Blood alkaline phosphatase increasedFAERS: 1US FAERS
48Blood creatinine increasedFAERS: 1US FAERS
49Blood triglycerides increasedFAERS: 1US FAERS
50C-reactive protein decreasedFAERS: 1US FAERS
51Cerebrovascular accidentFAERS: 1US FAERS
52Chest PainFAERS: 1US FAERS
53Clostridium difficile colitisFAERS: 1US FAERS
54Contraindicated product administeredFAERS: 1US FAERS
55Creatinine urine decreasedFAERS: 1US FAERS
56DeliriumFAERS: 1US FAERS
57Device related infectionFAERS: 1US FAERS
58DisorientationFAERS: 1US FAERS
59DizzinessFAERS: 1US FAERS
60Drug administered to patient of inappropriate ageFAERS: 1US FAERS
61Drug administration errorFAERS: 1US FAERS
62Drug level increasedFAERS: 1US FAERS
63Drug prescribing errorFAERS: 1US FAERS
64Drug screen negativeFAERS: 1US FAERS
65EmpyemaFAERS: 1US FAERS
66ErythemaFAERS: 1US FAERS
67FlushingFAERS: 1US FAERS
68Gamma-Glutamyltransferase IncreasedFAERS: 1US FAERS
69GoutFAERS: 1US FAERS
70HeadacheFAERS: 1US FAERS
71HemiparaesthesiaFAERS: 1US FAERS
72HypersensitivityFAERS: 1US FAERS
73Inappropriate schedule of drug administrationFAERS: 1US FAERS
74Intercepted medication errorFAERS: 1US FAERS
75Intestinal ObstructionFAERS: 1US FAERS
76Lip swellingFAERS: 1US FAERS
77Low Cardiac Output SyndromeFAERS: 1US FAERS
78Lung AbscessFAERS: 1US FAERS
79MalaiseFAERS: 1US FAERS
80Malignant neoplasm progressionFAERS: 1US FAERS
81Metabolic acidosisFAERS: 1US FAERS
82MetastasisFAERS: 1US FAERS
83Microbiology test abnormalFAERS: 1US FAERS
84Muscle RigidityFAERS: 1US FAERS
85Myocardial InfarctionFAERS: 1US FAERS
86NauseaFAERS: 1US FAERS
87NeutropeniaFAERS: 1US FAERS
88PalpitationsFAERS: 1US FAERS
89Poor quality product administeredFAERS: 1US FAERS
90Prescribed overdoseFAERS: 1US FAERS
91Procedural pneumothoraxFAERS: 1US FAERS
92Product dispensing errorFAERS: 1US FAERS
93Product label confusionFAERS: 1US FAERS
94Product label issueFAERS: 1US FAERS
95Product prescribing issueFAERS: 1US FAERS
96Product used for unknown indicationFAERS: 1US FAERS
97PyelonephritisFAERS: 1US FAERS
98Therapeutic response unexpectedFAERS: 1US FAERS
99UrticariaFAERS: 1US FAERS
100Vascular access malfunctionFAERS: 1US FAERS
101Wrong technique in product usage processFAERS: 1US FAERS
102nervous system disorderFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.